Search
Acetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalAcetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. … It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.
Factor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalAs the half-life of endogenous Factor XIII is long (5-11 days), prophylactic therapy with the replacement of FXIII can be given every 4-6 to maintain hemostasis[A32363]. … When activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit.
Products: Fibrogammin 1250 IE Pulver und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung, Fibrogammin 250 IE Pulver und Lösungsmittel zur Herstellung einer Injektions-/InfusionslösungFutibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigational[L43347] On July 4, 2023, the European Commission granted Conditional Marketing Authorization for futibatinib for the treatment of cholangiocarcinoma.[L47800] … [A253193,A253198] As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma.
Categories: Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitorsInotersen
go.drugbank.com/drugs/DB14713ApprovedInvestigationalHereditary transthyretin amyloidosis is caused by single-nucleotide variants in the gene encoding transthyretin (TTR), which lead to transthyretin misfolding and the deposition of amyloid substance systemically … Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults.
Enfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalEnfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake … The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
Terfenadine
go.drugbank.com/drugs/DB00342ApprovedWithdrawnIn the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Drometrizole trisiloxane
go.drugbank.com/drugs/DB11585ApprovedDespite being used elsewhere in the world with relatively few reports of adverse reactions, the FDA continues to cite that the existing scientific record is not sufficient to establish the compound as … The compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia
Octreotide
go.drugbank.com/drugs/DB00104ApprovedInvestigationalOn June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. … [L14501] Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone.
Categories: Somatostatin Receptor AgonistsProducts: SANDOSTATIN LAR 10 MG ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, SANDOSTATIN LAR 20 MG ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ VE ÇÖZÜCÜ, 1 ADETVibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalVibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. … Unlike mirabegron, vibegron is less likely to be associated with drug-drug interactions involving the CYP3A4, 2D6, or 2C9 enzymes.[A226065]
Categories: Adrenergic beta-3 Receptor AgonistsBepotastine
go.drugbank.com/drugs/DB04890ApprovedBepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. … The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.